Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
- PMID: 26598753
- DOI: 10.1200/JCO.2015.63.7801
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Abstract
Purpose: To explore racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer.
Methods: The National Cancer Data Base was queried to identify women with stage 1 to 3 breast cancer diagnosed in 2010 and 2011. Chemotherapy use and rate of pathologic complete response (pCR) was determined for various racial/ethnic groups.
Results: Of 278,815 patients with known race and ethnicity, 127,417 (46%) received chemotherapy, and of 121,446 where the timing of chemotherapy was known, 27,300 (23%) received neoadjuvant chemotherapy. Chemotherapy, and neoadjuvant chemotherapy in particular, was given more frequently to black, Hispanic, and Asian women than to white women (P < 0.001). This difference was largely explained by more advanced stage, higher grade tumors, and a greater proportion of triple-negative and human epidermal growth factor receptor 2 (HER2)-positive tumors in these women. Of 17,970 patients with known outcome, 5,944 (33%) had a pCR. No differences in response rate for estrogen receptor (ER)/progesterone receptor (PR)-positive tumors were found, but compared with white women, black but not Hispanic or Asian women had a lower rate of pCR for ER/PR-negative, HER2-positive (43% v 54%, P = 0.001) and triple-negative tumors (37% v 43%, P < 0.001). This difference persisted when adjusted for age, clinical T stage, clinical N stage, histology, grade, comorbidity index, facility type, geographic region, insurance status, and census-derived median income and education for the patient's zip code (odds ratio, 0.84; 95% CI, 0.77 to 0.93).
Conclusion: Neoadjuvant chemotherapy is given more frequently to black, Hispanic, and Asian women than to white women. Black women have a lower likelihood of pCR for triple-negative and HER2-positive breast cancer. Whether this is due to biologic differences in chemosensitivity or to treatment or socioeconomic differences that could not be adjusted for is unknown.
© 2015 by American Society of Clinical Oncology.
Similar articles
-
Racial Differences in Utilization of Breast Conservation Surgery: Results from the National Cancer Data Base (NCDB).Ann Surg Oncol. 2016 Oct;23(10):3272-83. doi: 10.1245/s10434-016-5475-x. Epub 2016 Aug 8. Ann Surg Oncol. 2016. PMID: 27503494
-
Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.J Natl Cancer Inst. 2012 Jul 18;104(14):1094-101. doi: 10.1093/jnci/djs264. Epub 2012 Jul 5. J Natl Cancer Inst. 2012. PMID: 22773826 Free PMC article.
-
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21. Cancer. 2013. PMID: 23436342 Free PMC article.
-
The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.J Womens Health (Larchmt). 2009 Jun;18(6):883-93. doi: 10.1089/jwh.2008.1127. J Womens Health (Larchmt). 2009. PMID: 19514831 Review.
-
Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis.Syst Rev. 2024 Apr 4;13(1):100. doi: 10.1186/s13643-024-02520-5. Syst Rev. 2024. PMID: 38576013 Free PMC article.
Cited by
-
Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses.Int J Gen Med. 2022 Jun 30;15:5901-5914. doi: 10.2147/IJGM.S370351. eCollection 2022. Int J Gen Med. 2022. PMID: 35795302 Free PMC article. Review.
-
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.J Clin Oncol. 2021 May 1;39(13):1485-1505. doi: 10.1200/JCO.20.03399. Epub 2021 Jan 28. J Clin Oncol. 2021. PMID: 33507815 Free PMC article.
-
Racial disparity in breast cancer: can it be mattered for prognosis and therapy.J Cell Commun Signal. 2018 Mar;12(1):119-132. doi: 10.1007/s12079-017-0416-4. Epub 2017 Nov 29. J Cell Commun Signal. 2018. PMID: 29188479 Free PMC article. Review.
-
A Prospective Population-Based Study of Cardiovascular Disease Mortality following Treatment for Breast Cancer among Men in the United States, 2000-2019.Curr Oncol. 2022 Dec 25;30(1):284-297. doi: 10.3390/curroncol30010023. Curr Oncol. 2022. PMID: 36661672 Free PMC article.
-
Efficacy of Neoadjuvant Versus Adjuvant Chemotherapy in Hispanic/Latino (H/L) Women With Local or Locally Advanced Triple-negative Breast Cancer (TNBC).In Vivo. 2019 Jul-Aug;33(4):1227-1234. doi: 10.21873/invivo.11594. In Vivo. 2019. PMID: 31280213 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous